ArticleJournal of thoracic disease2026
Endoscopic stenting as salvage therapy for high-risk Boerhaave's syndrome patients.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spontaneous oesophageal perforation (Boerhaave's syndrome) is a life-threatening emergency with significant morbidity and mortality. Surgical repair remains a key component of management for selected patients; however, many high-risk patients are unsuitable for operative management. This article discusses how, in these high-risk individuals, minimally invasive strategies such as the use of covered self-expanding metal stents (SEMS) offer a valuable alternative to surgery. Stent therapy aims to achieve rapid control of oesophageal leakage, limit mediastinal contamination, and facilitate early sepsis control. When applied in appropriately selected patients, this approach may reduce procedural morbidity while providing effective source control. Methods: This retrospective cohort study analysed all patients diagnosed with spontaneous oesophageal perforation between 2012 and 2024 at a tertiary referral centre. Patients deemed unfit for surgical intervention following comprehensive clinical assessment and acute multidisciplinary team (MDT) discussion-incorporating physiological status, comorbidities, Charlson Comorbidity Index (CCI), Pittsburgh score, markers of infection, and end-organ function-were managed with covered SEMS. Clinical, biochemical, and outcome data were reviewed. Results: Of 102 patients with oesophageal perforation, 69 were diagnosed with Boerhaave's syndrome. Twenty-two high-risk patients underwent endoscopic stenting with covered SEMS. The in-hospital mortality rate was 45%, predominantly from sepsis and multiorgan failure, while no deaths were directly stent-related. The 1-year survival rate was 50%. Conclusions: Endoscopic stenting offers a feasible and effective salvage option for high-risk Boerhaave's syndrome patients unsuitable for surgery. SEMS likely prevent otherwise inevitable fatalities in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.